动物造模,慢性心衰 z-bio 2022-07-20 376

　　OBJECTIVE: To study the effect and mechanism of liraglutide on cardiac function in pressure-stressed chronic heart failure rats.

　　Methods: Thirty SD rats were randomly divided into sham operation group, heart failure group and liraglutide group, 10 rats in each group. In the heart failure group and liraglutide group, the abdominal aortic coarctation method was used to prepare the model, and the sham operation group only had threading without coarctation. The liraglutide group was given subcutaneous injection of liraglutide 12 weeks after operation, 2 mg/kg·d for a total of 30 days. The sham operation group and the heart failure group were given the same dose of normal saline. After 30 days of administration, the rats were weighed, and the pressure-volume system was used to detect the hemodynamic indicators, and at the same time, the various organs of the rats were weighed. After the rats were anesthetized, blood was drawn from the abdominal aorta and centrifuged to obtain serum, and the superoxide dismutase (SOD), B-type natriuretic peptide (BNP) and malondialdehyde (MDA) were determined according to the kit method.

　　RESULTS: Heart weighing showed that the heart weight of the liraglutide group was significantly lower than that of the heart failure group (P<0.05). The hemodynamics detected by the pressure-volume system showed that compared with the sham-operated group, the Ves, Ved, Pmax, Pes, and Ped values of the liraglutide group were significantly decreased (P<0.05), dP/dt max, -dP/dt min, EF and PowMax values increased significantly (P<0.05). Compared with the heart failure group, the SOD value in the serum of the liraglutide group was significantly increased (P<0.05), while the BNP value was significantly decreased (P<0.05).

　　Conclusion: Liraglutide can improve the systolic and diastolic function of the left ventricle in rats with heart failure, and reduce the damage of myocardial cells, and the mechanism may be related to the antioxidant effect.